6 results on '"Ma, Gaini"'
Search Results
2. Association between ABC family polymorphisms and antidepressant response in Chinese Han population with major depressive disorder.
- Author
-
Ma, Gaini, Huang, Xiaoye, Xu, Fei, Ren, Decheng, Bi, Yan, Guo, Zhenming, Yuan, Fan, Sun, Qianqian, Zhang, Naixin, An, Lin, Chen, Zhixuan, Wu, Xi, Wang, Lu, Yang, Fengping, Li, Xingwang, He, Lin, Sun, Xueli, Yu, Tao, and He, Guang
- Subjects
- *
MENTAL depression , *ANTIDEPRESSANTS , *SEROTONIN uptake inhibitors - Published
- 2020
- Full Text
- View/download PDF
3. Interaction of CEND1 gene and life events in susceptibility to depressive symptoms in Chinese Han college students.
- Author
-
Hou, Binyin, Ji, Lei, Chen, Zhixuan, An, Lin, Zhang, Naixin, Ren, Decheng, Yuan, Fan, Liu, Liangjie, Bi, Yan, Guo, Zhenming, Ma, Gaini, Xu, Fei, Yang, Fengping, Yu, Shunying, Yi, Zhenghui, Xu, Yifeng, He, Lin, Liu, Chuanxin, Bai, Bo, and Yu, Tao
- Subjects
- *
MENTAL depression , *GENOTYPE-environment interaction , *SINGLE nucleotide polymorphisms , *LIFE change events , *COLLEGE students , *GENES , *RESEARCH , *RESEARCH methodology , *GENETIC polymorphisms , *MEDICAL cooperation , *EVALUATION research , *SELF-report inventories , *COMPARATIVE studies , *STEM cells , *DISEASE susceptibility , *GENOTYPES , *STUDENTS , *PHENOTYPES - Abstract
Background: . The development of depressive symptoms (DSs) is a complex process caused by both genetic and environmental factors. CEND1 gene coordinates cell division, differentiation and maturation of neural precursor cells, which affects brain structure and function. Our study investigated whether CEND1 was a genetic factor for DSs, particularly under negative life events.Methods: . 272 freshmen with DSs and 467 healthy controls were recruited via the Center for Epidemiologic Studies Depression Scale (CES-D). The adolescent Self-rating Life Event Checklist (ASLEC) was adopted to assess stressful life events during the past 12 months. Two SNPs (rs7946354, rs6597982) within the CEND1 gene were genotyped using Agena MassARRAY iPLEX technology. We combined generalized multifactor dimensionality reduction (GMDR) with RStudio programming to assess the direct association and gene-environment interaction (G × E).Results: . Rs7946354 was associated with DSs in an overdominant model (GT vs. GG+TT). In addition, both rs7946354 and rs6597982 had considerable impacts on negative life events. GMDR showed a statistical G × E that the AG genotype of rs6597982 and GT genotype of rs7946354 contribute to the maximum risk of DSs under high negative life events.Limitations: . Only two single nucleotide polymorphisms (SNPs) were examined. Verification studies with bigger sample size and more varied demographic background information could be adopted to further support the generalization of these findings.Conclusions: .CEND1 can potentially cause high sensitivity to life events and affect DSs especially in the presence of negative life events, which contribute to the field of depression prevention and treatment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. GSK-3β and BDNF genes may not be associated with venlafaxine treatment response in Chinese of Han ethnicity.
- Author
-
Sun, Qianqian, Yuan, Fan, Ren, Decheng, Ma, Gaini, Yang, Fengping, Wu, Xi, He, Lin, and He, Guang
- Subjects
- *
SINGLE nucleotide polymorphisms , *MENTAL depression , *FALSE discovery rate , *ETHNICITY , *GENE frequency - Abstract
Purpose: Venlafaxine is one of the commonly prescribed antidepressants for major depressive disorder (MDD). Accumulated evidence revealed the involvement of glutamatergic system in the pathophysiology of MDD and antidepressant treatment. Methods: We recruited 193 MDD patients who have been taking venlafaxine for 6 weeks, and investigated whether single nucleotide polymorphisms (SNPs) in GSK-3β and BDNF were associated with treatment response. Nine SNPs were selected randomly depending on association studies. Efficacy of treatment was determined by 17-item Hamilton Rating Scale. Allele and genotype frequencies were compared between responders and nonresponders. Results: After adjusting the false discovery rate, no significant difference was observed between response and nonresponse groups in allele or genotype distributions after venlafaxine treatment for 6 weeks. Conclusion: Our results indicated that genetic variants in the GSK-3β and BDNF may not be associated with treatment response in MDD patients treated with venlafaxine. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
- Author
-
Bi, Yan, Ren, Decheng, Guo, Zhenming, Ma, Gaini, Xu, Fei, Chen, Zhixuan, An, Lin, Zhang, Naixin, Ji, Lei, Yuan, Fan, Liu, Liangjie, Hou, Binyin, Yang, Fengping, Yu, Shunying, Yi, Zhenghui, Xu, Yifeng, He, Lin, Sun, Xueli, Dong, Zaiquan, and Wu, Shaochang
- Subjects
- *
ANTIDEPRESSANTS , *MENTAL depression , *CHINESE people , *SEROTONIN uptake inhibitors , *TRICYCLIC antidepressants , *TREATMENT effectiveness - Abstract
Despite there is a wide range of antidepressants available, with various mechanisms of actions, the efficacy of current therapeutic options is yet satisfactory. Previous shreds of evidence have indicated that genetics, cognitive, neuroendocrine, as well as personality factors, are all intrinsically linked and contribute to the diversity of treatment outcomes. We, therefore, sought to investigate this hypothesis in this study. Based on 610 samples treated with a selection of serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), noradrenergic and specific serotonergic antidepressant (NaSSA) or tricyclic antidepressant (TCA), we compared the therapeutic effects of these four classes of drugs by survival analyses. Pharmacogenomic and survival analyses were carried out to explore the hereditary factors for curative effect and the accumulation of genetic factors was further discussed through pathway analysis and the global test. We built a machine learning-based prediction model that integrates genetic and non-genetic factors (including cognition, endocrinology, personality intelligence) to distinguish drug efficacy in single class drug situations. The values of the non-genetic makers after 6 weeks' treatment were collected to evaluate the efficacy of the model. Our results from the 6-week antidepressant therapeutic study indicated that SSRI and SNRI are better treatments than those of TCA and NaSSA in the Chinese population. Among all possible paired single-agent survival analyses, citalopram and venlafaxine were more effective than mirtazapine. Allele C carriers at rs6354 (SLC6A4) and allele G carriers at rs12150214 (SLC6A4) were significantly prone to poorer treatment response to fluoxetine. Besides, the combination of three loci (rs929377-rs6191-rs32897) located in HPA pathway was significantly associated with the treatment outcome of fluoxetine. In female MDD patients, the minor allele of rs6323 and rs1137070 on the MAOA gene likely lead to a worse response to venlafaxine. Furthermore, genetic variants linked to drug efficacy tended to concentrate on the neurotrophin pathway in depressed patients comorbid with anxiety. From multivariate models, more severe cognitive deficits, psychopathic personality and lower levels of operational intelligence, and higher levels of cortisol predicted worse response status with SSRI or SNRI after 6-week treatment. Notably, genetic factors in the multi-dimensional prediction model for both classes of drugs include loci in HTR2A and CRHBP genes. SSRI and SNRI are more suitable for the treatment of Chinese people with depression. SLC6A4 genetic variants, as well as HPA pathway, play an important role in the fluoxetine antidepressant therapeutic response while the polymorphism of MAOA gene involved in the pharmacological action of venlafaxine among female MDD patients. The presence of anxiety in MDD patients was related to the neurotrophin pathway. Genetic, cognitive, neuroendocrine, and personality intelligence factors combined have an ensemble impact on the medication effect of patients with major depression, leading to more precise and personalized medicine for specific groups of people. • SSRI and SNRI are better treatments in the Chinese population • SLC6A4 gene and HPA pathway play an important role in the fluoxetine antidepressant therapeutic response • The polymorphism of MAOA gene involved in the pharmacological action of venlafaxine among female patients • anxiety in MDD patients was related to the neurotrophin pathway • Genetic, cognition and concomitant symptom are critical factors in the selection of antidepressants for specific patients [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.
- Author
-
Yuan, Fan, Yuan, Ruixue, Ren, Decheng, Bi, Yan, Niu, Weibo, Guo, Zhenming, Wu, Xi, Xu, Fei, Sun, Qianqian, Ma, Gaini, Yang, Fengping, Zhu, Yuhao, Yu, Tao, Li, Xingwang, He, Lin, Shi, Lei, and He, Guang
- Subjects
- *
TREATMENT effectiveness , *SINGLE nucleotide polymorphisms , *MENTAL depression , *ADRENOCORTICOTROPIC hormone , *GENETIC polymorphisms - Abstract
Objective: We aimed to study the association among venlafaxine antidepressive outcome, NR3C2 gene polymorphisms and the change of two neuroendocrine hormones during treatment. Methods: 195 Chinese Han major depressive disorder (MDD) patients were recruited and received a 6-week venlafaxine treatment in this study. Adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH) levels were measured at the beginning and at the end of treatment. Six single-nucleotide polymorphisms (SNPs) (NR3C2 : rs1512325, rs1512342, rs2070951; NR3C1 : rs6191, rs6196, rs10482614) were selected for high-throughput SNP genotyping. Allele and genotype frequencies of them were compared between remission and non-remission groups. Results: We found that genotype frequency of the rs1512325 located in the NR3C2 gene was significantly different between remission and non-remission groups respectively (p < 0.05). Meanwhile, the frequency of the rs1512325 C-allele was significantly lower (p < 0.05) in remission group. The TSH concentration significantly increased after venlafaxine treatment in remission group (p < 0.05). Conclusion: The rs1512325 in NR3C2 gene and TSH concentration may be related to venlafaxine treatment outcome in Chinese Han MDD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.